How Endo International’s Gross Margin Has Trended

Endo International’s (ENDP) next two business segments are: The US Generic Pharmaceuticals segment includes solid oral extended release, solid oral immediate release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. Revenues from this segment declined from $294.75 million in the third quarter of 2017 to $257.97 million in the third quarter of 2018. The International Pharmaceuticals segment revenues also declined from $56.43 million in the third quarter of 2017 to $30.25 million in the third quarter of 2018.